OSTX
OS Therapies Incorporated
Price Chart
Latest Quote
$1.82
-0.11 (-5.70%)
Current Price
| Previous Close | $1.93 |
| Open | $1.91 |
| Day High | $1.92 |
| Day Low | $1.82 |
| Volume | 365,569 |
Stock Information
| Shares Outstanding | 44.54M |
| Total Debt | $1.34M |
| Cash Equivalents | $918K |
| Net Income | $-35.27M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $81.06M |
| EPS (TTM) | $-1.07 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $82.56M |
| Income | $-35.27M |
| Book/sh | $-0.28 |
| Cash/sh | $0.02 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 0.05 |
| Current Ratio | 0.05 |
Returns & Margins
| ROA | -366.63% |
Ownership
| Insider Ownership | 22.14% |
| Institutional Ownership | 6.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.47 |
| P/B | -6.59 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $9.40 |
Technical Indicators
| SMA20 | $1.81 |
| SMA50 | $1.69 |
| SMA200 | $1.68 |
| RSI | 46.75 |
| ATR | 0.1322 |
| Shares Float | 36.21M |
| Short Float | 4.02% |
| Short Ratio | 2.32 |
| Rel Volume | 0.55 |
Performance History
| Week | +7.06% |
| Month | -0.55% |
| Quarter | +18.18% |
| 6 Months | +18.18% |
| YTD | +35.82% |
| Year | +0.00% |
| 10 Years | -27.49% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $1.82 | 388,600 |
| 2026-06-18 | $1.93 | 1,145,100 |
| 2026-06-17 | $1.72 | 470,800 |
| 2026-06-16 | $1.77 | 1,090,900 |
| 2026-06-15 | $1.72 | 169,300 |
| 2026-06-12 | $1.70 | 279,400 |
| 2026-06-11 | $1.71 | 364,800 |
| 2026-06-10 | $1.69 | 302,300 |
| 2026-06-09 | $1.74 | 365,700 |
| 2026-06-08 | $1.79 | 494,800 |
| 2026-06-05 | $1.78 | 593,300 |
| 2026-06-04 | $1.85 | 385,400 |
| 2026-06-03 | $1.80 | 624,400 |
| 2026-06-02 | $1.83 | 1,655,700 |
| 2026-06-01 | $1.87 | 1,827,000 |
| 2026-05-29 | $2.14 | 1,457,700 |
| 2026-05-28 | $1.98 | 975,800 |
| 2026-05-27 | $1.89 | 726,100 |
| 2026-05-26 | $1.75 | 445,100 |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $2,051,839 | $3,448,939 | $1,808,386 |
| Total Expenses | $28,705,701 | $6,813,846 | $4,342,645 | $4,446,299 |
| Other Income Expense | $-48,392 | $-17,253 | - | - |
| Other Non Operating Income Expenses | $-1,472,995 | $-17,253 | - | - |
| Net Non Operating Interest Income Expense | $249 | $-2,051,839 | $-3,448,937 | $-1,808,386 |
| Interest Expense Non Operating | $0 | $2,051,839 | $3,448,939 | $1,808,386 |
| Operating Expense | $28,705,701 | $6,813,846 | $4,342,645 | $4,446,299 |
| General And Administrative Expense | $12,344,976 | $3,974,786 | $1,125,712 | $1,153,672 |
| Other Operating Expenses | - | - | $5,154 | $1,210 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-28,753,844 | $-8,882,938 | $-7,791,582 | $-6,254,685 |
| Net Interest Income | $249 | $-2,051,839 | $-3,448,937 | $-1,808,386 |
| Interest Income | $249 | $0 | $2 | $0 |
| Normalized Income | $-30,178,447 | $-8,882,938 | $-7,791,582 | $-6,254,685 |
| Net Income From Continuing And Discontinued Operation | $-28,753,844 | $-8,882,938 | $-7,791,582 | $-6,254,685 |
| Total Operating Income As Reported | $-28,705,701 | $-6,813,846 | $-4,342,645 | $-4,446,299 |
| Net Income Common Stockholders | $-28,753,844 | $-8,914,188 | $-7,916,582 | $-6,379,685 |
| Net Income | $-28,753,844 | $-8,882,938 | $-7,791,582 | $-6,254,685 |
| Net Income Including Noncontrolling Interests | $-28,753,844 | $-8,882,938 | $-7,791,582 | $-6,254,685 |
| Net Income Continuous Operations | $-28,753,844 | $-8,882,938 | $-7,791,582 | $-6,254,685 |
| Pretax Income | $-28,753,844 | $-8,882,938 | $-7,791,582 | $-6,254,685 |
| Interest Income Non Operating | $249 | $0 | $2 | $0 |
| Operating Income | $-28,705,701 | $-6,813,846 | $-4,342,645 | $-4,446,299 |
| Per Share | ||||
| Diluted EPS | $-0.98 | $-1.28 | $-0.38 | $-0.32 |
| Basic EPS | $-0.98 | $-1.28 | $-0.38 | $-0.32 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-29,815,362 | $-6,828,319 | $-4,338,423 | $-4,445,494 |
| Total Unusual Items | $1,424,603 | - | - | - |
| Total Unusual Items Excluding Goodwill | $1,424,603 | - | - | - |
| Reconciled Depreciation | $363,085 | $2,780 | $4,220 | $805 |
| EBITDA (Bullshit earnings) | $-28,390,759 | $-6,828,319 | $-4,338,423 | $-4,445,494 |
| EBIT | $-28,753,844 | $-6,831,099 | $-4,342,643 | $-4,446,299 |
| Diluted Average Shares | $29,253,292 | $6,950,100 | $20,597,777 | $20,049,655 |
| Basic Average Shares | $29,253,292 | $6,950,100 | $20,597,777 | $20,049,655 |
| Diluted NI Availto Com Stockholders | $-28,753,844 | $-8,914,188 | $-7,916,582 | $-6,379,685 |
| Gain On Sale Of Security | $1,424,603 | - | - | - |
| Research And Development | $16,360,725 | $2,839,060 | $3,216,933 | $3,291,417 |
| Selling General And Administration | $12,344,976 | $3,974,786 | $1,125,712 | $1,153,672 |
| Other Gand A | $12,344,976 | $3,974,786 | $1,125,712 | $1,153,672 |
| Preferred Stock Dividends | - | $31,250 | $125,000 | $125,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-12,599,763 | $-3,266,538 | $-24,016,215 | $-17,557,228 |
| Total Assets | $6,839,534 | $5,538,797 | $798,082 | $509,105 |
| Total Non Current Assets | $6,506,622 | $5,270 | $8,050 | $12,270 |
| Goodwill And Other Intangible Assets | $6,504,132 | $0 | - | - |
| Other Intangible Assets | $6,504,132 | - | - | - |
| Current Assets | $332,912 | $5,533,527 | $790,032 | $496,835 |
| Prepaid Assets | $63,082 | $0 | - | $0 |
| Cash Cash Equivalents And Short Term Investments | $269,830 | $5,533,527 | $38,982 | $171,480 |
| Cash And Cash Equivalents | $269,830 | $5,533,527 | $38,982 | $171,480 |
| Cash Financial | $269,830 | $5,533,527 | $38,982 | $171,480 |
| Current Deferred Assets | - | $0 | $751,050 | $324,210 |
| Receivables | - | - | $0 | $1,145 |
| Loans Receivable | - | - | $0 | $1,145 |
| Debt | ||||
| Net Debt | - | - | $14,571,359 | $10,176,152 |
| Total Debt | - | - | $14,610,341 | $10,347,632 |
| Current Debt And Capital Lease Obligation | - | - | $14,610,341 | - |
| Current Debt | - | - | $14,610,341 | - |
| Other Current Borrowings | - | - | $14,610,341 | - |
| Long Term Debt And Capital Lease Obligation | - | - | - | $10,347,632 |
| Long Term Debt | - | - | - | $10,347,632 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,935,165 | $8,805,335 | $24,814,297 | $18,066,333 |
| Total Non Current Liabilities Net Minority Interest | $1,170,705 | $4,178,025 | $100,000 | $11,918,541 |
| Non Current Deferred Liabilities | $100,000 | $100,000 | $100,000 | $100,000 |
| Current Liabilities | $11,764,460 | $4,627,310 | $24,714,297 | $6,147,792 |
| Payables And Accrued Expenses | $11,764,460 | $2,655,335 | $5,393,652 | $3,108,738 |
| Payables | $10,311,387 | $2,037,068 | $3,059,149 | $1,443,884 |
| Dividends Payable | $375,000 | $375,000 | $343,750 | $218,750 |
| Accounts Payable | $9,936,387 | $1,662,068 | $2,715,399 | $1,225,134 |
| Other Current Liabilities | - | $1,971,975 | $4,710,304 | $3,039,054 |
| Interest Payable | - | $0 | $2,026,323 | $1,223,843 |
| Other Non Current Liabilities | - | - | - | $1,470,909 |
| Total Tax Payable | - | - | - | $426,011 |
| Equity | ||||
| Common Stock Equity | $-6,095,631 | $-3,266,538 | $-24,017,517 | $-17,558,530 |
| Total Equity Gross Minority Interest | $-6,095,631 | $-3,266,538 | $-24,016,215 | $-17,557,228 |
| Stockholders Equity | $-6,095,631 | $-3,266,538 | $-24,016,215 | $-17,557,228 |
| Retained Earnings | $-67,186,219 | $-38,432,375 | $-29,518,187 | $-21,601,603 |
| Preferred Securities Outside Stock Equity | $1,070,705 | $4,078,025 | $0 | - |
| Preferred Stock Equity | - | $6,050,000 | $1,302 | $1,302 |
| Other | ||||
| Ordinary Shares Number | $37,113,082 | $20,869,908 | $20,597,777 | $20,597,777 |
| Share Issued | $37,113,082 | $20,869,908 | $20,597,777 | $20,597,777 |
| Tangible Book Value | $-12,599,763 | $-3,266,538 | $-24,017,517 | $-17,558,530 |
| Invested Capital | $-6,095,631 | $-3,266,538 | $-9,407,176 | $-7,210,898 |
| Working Capital | $-11,431,548 | $906,217 | $-23,924,265 | $-5,650,957 |
| Total Capitalization | $-6,095,631 | $-3,266,538 | $-24,016,215 | $-7,209,596 |
| Additional Paid In Capital | $61,053,472 | $35,144,967 | $5,495,330 | $4,038,083 |
| Capital Stock | $37,116 | $20,870 | $6,642 | $6,292 |
| Common Stock | $37,116 | $20,870 | $5,340 | $4,990 |
| Preferred Stock | $0 | $0 | $1,302 | $1,302 |
| Non Current Deferred Revenue | $100,000 | $100,000 | $100,000 | $100,000 |
| Current Accrued Expenses | $1,453,073 | $618,267 | $2,334,503 | $1,664,854 |
| Net PPE | $2,490 | $5,270 | $8,050 | $12,270 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-14,704,999 | $-7,282,295 | $-3,006,967 | $-3,792,580 |
| Operating Activities | ||||
| Operating Cash Flow | $-14,238,576 | $-7,282,295 | $-3,006,967 | $-3,792,580 |
| Cash Flow From Continuing Operating Activities | $-14,238,576 | $-7,282,295 | $-3,006,967 | $-3,792,580 |
| Operating Gains Losses | $-1,424,603 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-466,423 | - | - | - |
| Investing Cash Flow | $-466,423 | $0 | $1,145 | $230,881 |
| Cash Flow From Continuing Investing Activities | $-466,423 | $0 | $1,145 | $230,881 |
| Net Other Investing Changes | - | - | $1,145 | $230,881 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,911,140 | $11,275,840 | $0 | - |
| Financing Cash Flow | $9,441,302 | $12,776,840 | $2,873,324 | $3,652,391 |
| Cash Flow From Continuing Financing Activities | $9,441,302 | $12,776,840 | $2,873,324 | $3,652,391 |
| Net Preferred Stock Issuance | $1,053,000 | $6,050,000 | $0 | - |
| Preferred Stock Issuance | $1,053,000 | $6,050,000 | $0 | - |
| Net Common Stock Issuance | $7,858,140 | $5,225,840 | $0 | - |
| Common Stock Issuance | $7,858,140 | $5,225,840 | $0 | - |
| Net Other Financing Charges | - | - | $-284,176 | $-172,021 |
| Other | ||||
| Repayment Of Debt | $0 | $-250,000 | $0 | - |
| Issuance Of Debt | $0 | $1,751,000 | $3,157,500 | $3,824,412 |
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $269,830 | $5,533,527 | $38,982 | $171,480 |
| Beginning Cash Position | $5,533,527 | $38,982 | $171,480 | $80,788 |
| Changes In Cash | $-5,263,697 | $5,494,545 | $-132,498 | $90,692 |
| Proceeds From Stock Option Exercised | $530,162 | $0 | - | - |
| Net Issuance Payments Of Debt | $0 | $1,501,000 | $3,157,500 | $3,824,412 |
| Net Short Term Debt Issuance | $0 | $0 | $0 | - |
| Short Term Debt Payments | $0 | $-250,000 | $0 | - |
| Short Term Debt Issuance | $0 | $250,000 | $0 | - |
| Net Long Term Debt Issuance | $0 | $1,501,000 | $3,157,500 | $3,824,412 |
| Long Term Debt Issuance | $0 | $1,501,000 | $3,157,500 | $3,824,412 |
| Net Intangibles Purchase And Sale | $-466,423 | $0 | - | - |
| Purchase Of Intangibles | $-466,423 | $0 | - | - |
| Change In Working Capital | $9,109,122 | $-129,639 | $2,017,248 | $947,330 |
| Change In Payables And Accrued Expense | $9,109,122 | $-129,639 | $2,017,248 | $947,330 |
| Change In Accrued Expense | $834,806 | $923,692 | $669,646 | $730,904 |
| Change In Interest Payable | $0 | $613,605 | $802,479 | $656,913 |
| Change In Payable | $8,274,316 | $-1,053,331 | $1,347,602 | $216,426 |
| Change In Account Payable | $8,274,316 | $-1,053,331 | $1,347,602 | $216,426 |
| Other Non Cash Items | $1,605,866 | $1,459,202 | $2,763,147 | $1,513,970 |
| Stock Based Compensation | $4,861,798 | $268,300 | $0 | - |
| Depreciation Amortization Depletion | $363,085 | $2,780 | $4,220 | $805 |
| Depreciation And Amortization | $363,085 | $2,780 | $4,220 | $805 |
| Depreciation | $363,085 | $2,780 | $4,220 | $805 |
| Gain Loss On Investment Securities | $-1,424,603 | - | - | - |
| Net Income From Continuing Operations | $-28,753,844 | $-8,882,938 | $-7,791,582 | $-6,254,685 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $0 |
Fetched: 2026-06-23